FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308506106> ?p ?o ?g. }

• W4308506106 abstract "Cancer-associated venous thromboembolism (VTE) has exhibited a rising incidence rate. Research focusing on cancer-associated VTE and current anticoagulation therapy strategies is limited. The present study aimed to investigate the prevalence, characteristics and anticoagulation therapy strategies of cancer-associated VTE. The study was performed on patients with major solid tumors who were admitted to The First Affiliated Hospital of Guangxi Medical University (Nanning, China) between January 2020 and December 2020. The medical records of the patients' demographic characteristics, disease and treatment were extracted from the medical record data system and reviewed. The prevalence of cancer-associated VTE was calculated, followed by statistical analysis. Patients who received anticoagulation therapy for cancer-associated VTE were followed up for 1 year. The characteristics and efficacy of anticoagulation therapy strategies were compared and analyzed. A total of 4,926 patients with major solid tumors (mean age, 55.86±11.97 years) were included in the analysis, of which 117 (2.4%; 117/4,926) were diagnosed with cancer-associated VTE. Patients with pancreatic cancer exhibited the highest prevalence of VTE (10.2%; 5/49), followed by patients with ovarian cancer (5.8%; 9/156) and lung cancer (3.3; 73/2,237). Multivariate analysis identified hypertension comorbidity [odds ratio (OR), 1.661; 95% CI, 1.031-2.674; P=0.037)] and cancer stage (OR, 1.266; 95% CI, 1.079-1.486; P=0.004) as independent risk factors for cancer-associated VTE. Deep vein thrombosis (DVT) of the lower extremity accounted for 62.0%; 62/100) of all DVTs. Moreover, pulmonary embolism (PE) with lower extremity DVT accounted for 53.5% (23/43) of all PE cases. The majority of cancer-associated VTE cases (63.2%; 74/117) developed 30 days before or after a cancer diagnosis. In addition, cancer-associated VTE was dominated by symptomatic VTE (59.8%; 70/117). Only 74.4% (87/117) of patients with VTE received anticoagulant treatment, with a median duration of 79 days. The most common anticoagulant treatment strategies were heparin during hospitalization and direct oral anticoagulants (rivaroxaban) after discharge. The anticoagulants associated with bleeding events were rivaroxaban (4.2%; 3/72) and enoxaparin (1.9%; 1/54). In total, 62.1% (36/58) of the patients received anticoagulant treatment for <90 days. In conclusion, the results indicated that the prevalence of cancer-associated VTE is common and exhibits numerous characteristics. Rivaroxaban has been widely used in cancer-associated VTE treatment. However, compliance with long-term anticoagulant treatment is not adequate at present, while the efficacy and safety of rivaroxaban must be evaluated to improve long-term medication monitoring and follow-up among patients with cancer-associated VTE." @default.
• W4308506106 created "2022-11-12" @default.
• W4308506106 creator A5009158783 @default.
• W4308506106 creator A5018204586 @default.
• W4308506106 creator A5029063335 @default.
• W4308506106 creator A5036656406 @default.
• W4308506106 creator A5039045403 @default.
• W4308506106 creator A5048507557 @default.
• W4308506106 creator A5065490860 @default.
• W4308506106 creator A5078713800 @default.
• W4308506106 date "2022-11-03" @default.
• W4308506106 modified "2023-10-01" @default.
• W4308506106 title "Prevalence and treatment of venous thromboembolism in patients with solid tumors" @default.
• W4308506106 cites W1524100482 @default.
• W4308506106 cites W1589295587 @default.
• W4308506106 cites W2074738578 @default.
• W4308506106 cites W2113160384 @default.
• W4308506106 cites W2313284959 @default.
• W4308506106 cites W2410257616 @default.
• W4308506106 cites W2466838272 @default.
• W4308506106 cites W2490019007 @default.
• W4308506106 cites W2529667944 @default.
• W4308506106 cites W2553583882 @default.
• W4308506106 cites W2586743405 @default.
• W4308506106 cites W2748990043 @default.
• W4308506106 cites W2897723485 @default.
• W4308506106 cites W2901744711 @default.
• W4308506106 cites W2913336223 @default.
• W4308506106 cites W2924354627 @default.
• W4308506106 cites W2932112037 @default.
• W4308506106 cites W2942676757 @default.
• W4308506106 cites W2945731413 @default.
• W4308506106 cites W2966354200 @default.
• W4308506106 cites W2966694602 @default.
• W4308506106 cites W2973632923 @default.
• W4308506106 cites W2983987032 @default.
• W4308506106 cites W3037161220 @default.
• W4308506106 cites W3045845087 @default.
• W4308506106 cites W3100796456 @default.
• W4308506106 cites W3106658258 @default.
• W4308506106 cites W3112056869 @default.
• W4308506106 cites W3116137186 @default.
• W4308506106 cites W3119239593 @default.
• W4308506106 cites W3123912640 @default.
• W4308506106 cites W3163733220 @default.
• W4308506106 cites W3173952575 @default.
• W4308506106 cites W4211103741 @default.
• W4308506106 cites W4212905021 @default.
• W4308506106 doi "https://doi.org/10.3892/etm.2022.11679" @default.
• W4308506106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36478882" @default.
• W4308506106 hasPublicationYear "2022" @default.
• W4308506106 type Work @default.
• W4308506106 citedByCount "1" @default.
• W4308506106 countsByYear W43085061062023 @default.
• W4308506106 crossrefType "journal-article" @default.
• W4308506106 hasAuthorship W4308506106A5009158783 @default.
• W4308506106 hasAuthorship W4308506106A5018204586 @default.
• W4308506106 hasAuthorship W4308506106A5029063335 @default.
• W4308506106 hasAuthorship W4308506106A5036656406 @default.
• W4308506106 hasAuthorship W4308506106A5039045403 @default.
• W4308506106 hasAuthorship W4308506106A5048507557 @default.
• W4308506106 hasAuthorship W4308506106A5065490860 @default.
• W4308506106 hasAuthorship W4308506106A5078713800 @default.
• W4308506106 hasBestOaLocation W43085061061 @default.
• W4308506106 hasConcept C120665830 @default.
• W4308506106 hasConcept C121332964 @default.
• W4308506106 hasConcept C121608353 @default.
• W4308506106 hasConcept C126322002 @default.
• W4308506106 hasConcept C156957248 @default.
• W4308506106 hasConcept C195910791 @default.
• W4308506106 hasConcept C2776256026 @default.
• W4308506106 hasConcept C2778959117 @default.
• W4308506106 hasConcept C2779159551 @default.
• W4308506106 hasConcept C2780011451 @default.
• W4308506106 hasConcept C2780868729 @default.
• W4308506106 hasConcept C61511704 @default.
• W4308506106 hasConcept C71924100 @default.
• W4308506106 hasConceptScore W4308506106C120665830 @default.
• W4308506106 hasConceptScore W4308506106C121332964 @default.
• W4308506106 hasConceptScore W4308506106C121608353 @default.
• W4308506106 hasConceptScore W4308506106C126322002 @default.
• W4308506106 hasConceptScore W4308506106C156957248 @default.
• W4308506106 hasConceptScore W4308506106C195910791 @default.
• W4308506106 hasConceptScore W4308506106C2776256026 @default.
• W4308506106 hasConceptScore W4308506106C2778959117 @default.
• W4308506106 hasConceptScore W4308506106C2779159551 @default.
• W4308506106 hasConceptScore W4308506106C2780011451 @default.
• W4308506106 hasConceptScore W4308506106C2780868729 @default.
• W4308506106 hasConceptScore W4308506106C61511704 @default.
• W4308506106 hasConceptScore W4308506106C71924100 @default.
• W4308506106 hasIssue "6" @default.
• W4308506106 hasLocation W43085061061 @default.
• W4308506106 hasLocation W43085061062 @default.
• W4308506106 hasLocation W43085061063 @default.
• W4308506106 hasOpenAccess W4308506106 @default.
• W4308506106 hasPrimaryLocation W43085061061 @default.
• W4308506106 hasRelatedWork W1977732319 @default.
• W4308506106 hasRelatedWork W2007172212 @default.
• W4308506106 hasRelatedWork W2016360538 @default.
• W4308506106 hasRelatedWork W2076461938 @default.

• next